StockData
LB Pharmaceuticals Inc logo

LB Pharmaceuticals Inc (LBRX) stock

LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$38.85−1.19 (-2.97%)

Close on Nov 20, 2026Market cap $1.25BP/E –Yield –

LB Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

LB Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$82.83M. For fiscal 2025 it was -$35.26M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$35.26M–
FY2024Dec 31, 2024-$53.82M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$37.99M–
Q1 FY2026Mar 31, 2026-$23.32M–
Q4 FY2025Dec 31, 2025-$18.14M–
Q3 FY2025Sep 30, 2025-$3.37M–
Q2 FY2025Jun 30, 2025-$5.60M–
Q1 FY2025Mar 31, 2025-$8.15M–
Q4 FY2024Dec 31, 2024-$5.90M–

More LB Pharmaceuticals figures

See a number that looks wrong?